Proactive therapeutic drug monitoring of infliximab: a comparative study of a new point‐of‐care quantitative test with two established <scp>ELISA</scp> assays

The Quantum Blue IFX assay can successfully replace the commonly used ELISA-based IFX quantification kits. This point-of-care IFX assay is able to deliver the results within 15 min makes it ideal for an immediate target concentration adjusted dosing. Moreover, it is a user-friendly desktop device that does not require specific laboratory facilities or highly specialised personnel.